Living with aTTP? Join a national patient registry study
Part of Blood & lymphatic clinical trials.
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with acquired TTP (aTTP) on or after January 1, 2015
- Your ADAMTS13/ADAMS13 level is under 10% (a lab marker related to TTP)
- Your platelet count is low (less than 100,000)
- You have signs of anemia from small-vessel damage (microangiopathic hemolytic anemia)
- You are 18 years or older and can sign the informed consent form
- Your Coombs test is negative (Coombs negative)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
Hear when a new TTP - Thrombotic Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.